Compass Therapeutics(NASDAQ) CMPX

Compass Therapeutics, Inc. develops new medicines to fight cancer. These treatments help the body stop tumors from growing. The company assists patients who need better treatment options.

What's in the Pipeline?

• Tovecimig (CTX-009): Bispecific antibody that blocks proteins called Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) to stop tumor blood supply.
• CTX-471: Monoclonal antibody that activates a co-stimulatory receptor known as CD-137 found on immune cells to attack cancer.
• CTX-8371: Bispecific antibody targeting PD-1 and PD-L1, which are proteins tumors use to hide from the immune system.
• CTX-10726: Clinical candidate that combines immune system activation and blood vessel blockage into a single medicine.

Recent Clinical Milestones

• Announced survival and safety data from a Phase 2/3 study for tovecimig in patients with biliary tract cancer in April 2026.
• Initiated two investigator-sponsored trials for tovecimig in colorectal cancer and glioblastoma.
• Presented dose-escalation results for CTX-8371 at a major oncology conference in May 2026.
• Dosed the first patients in a Phase 1 study of CTX-10726 for several advanced solid tumors.
• Entered a new agreement for an at-the-market stock offering with Leerink Partners LLC and Cantor Fitzgerald in December 2025.

Dual-Action Antibody Science

The company focuses on how tumors grow blood vessels and hide from the immune system. It builds special proteins called bispecific antibodies that can attack two different parts of a tumor at once.

The Latest Financial Results

• Cash, cash equivalents, and marketable securities reached $180 million as of June 30, 2026.
• Net loss for the six-month period ended June 30, 2026, was $43.5 million.
• Research and development spending reached $33.0 million for the six months ended June 30, 2026, up 12% year over year.
• Market capitalization was $408.7 million in Q2 2026, up 13.7% year over year.
• Accumulated deficit reached $475 million as of June 30, 2026.

Bottom Line

Compass Therapeutics has evolved into a clinical-stage developer with a lead candidate approaching a potential regulatory filing. Its portfolio of multitarget antibodies aims to address diverse oncology needs through both internal and investigator-led trials.